Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Deffered Revenue (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $12.5 million as the latest value for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 44.53% to $12.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Sep 2025, down 44.53% year-over-year, with the annual reading at $18.3 million for FY2024, 53.01% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $12.5 million at Intellia Therapeutics, roughly flat from $12.5 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $63.5 million in Q4 2021, with the low at $12.5 million in Q2 2025.
  • Average Non-Current Deffered Revenue over 5 years is $29.6 million, with a median of $25.7 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue soared 251.99% in 2021, then plummeted 71.99% in 2023.
  • Over 5 years, Non-Current Deffered Revenue stood at $63.5 million in 2021, then tumbled by 68.6% to $19.9 million in 2022, then skyrocketed by 94.93% to $38.9 million in 2023, then plummeted by 53.01% to $18.3 million in 2024, then tumbled by 31.32% to $12.5 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $12.5 million, $12.5 million, and $13.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.